Finerenone for Regression of Albuminuria in Type 2 Diabetes With Chronic Kidney Disease
Efficacy and Safety of Finerenone for the Early Regression of Albuminuria in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
Přehled studie
Postavení
Postavení
Podmínky
Podmínky
Intervence / Léčba
Intervence / Léčba
Detailní popis
Background and rationale: Finerenone is an oral, highly selective nonsteroidal mineralocorticoid receptor antagonist approved in China for the treatment of chronic kidney disease associated with type 2 diabetes (with albuminuria). In the phase III FIDELIO-DKD and FIGARO-DKD trials, finerenone added to a maximum tolerated dose of a renin-angiotensin system inhibitor significantly and durably reduced the urine albumin-to-creatinine ratio (UACR) and lowered the risk of kidney and cardiovascular events, with a manageable hyperkalemia risk. A meaningful reduction in albuminuria is an established early surrogate for slowing CKD progression and reducing cardiovascular risk. This study evaluates whether finerenone can achieve early regression of albuminuria in patients with type 2 diabetes and CKD.
Design: This is a multicenter, randomized, double-blind, placebo-controlled trial conducted at up to 12 sites in China. A planned 148 participants are allocated 1:1 to finerenone or matching placebo using central, block randomization (interactive response technology), stratified by baseline UACR (<300 vs >=300 mg/g). Participants and investigators are blinded; placebo tablets are identical in appearance to finerenone, and intervention-period UACR samples are assayed centrally after study completion to preserve blinding.
Population: Eligible participants are adults with type 2 diabetes and CKD (eGFR >= 30 mL/min/1.73 m^2 and UACR 30-2000 mg/g) who have received a maximum tolerated dose of an ACE inhibitor or ARB for at least 90 days and have serum potassium <= 5.0 mmol/L.
Intervention and dose titration: The starting dose is determined by screening eGFR: 10 mg once daily for 30 <= eGFR < 60 mL/min/1.73 m^2, or 20 mg once daily for eGFR >= 60 mL/min/1.73 m^2. The dose is up-titrated to 20 mg, maintained, interrupted, or down-titrated to 10 mg based on serum potassium and eGFR at scheduled and, if needed, unscheduled safety visits. Treatment continues for 180 days.
Visit schedule: a screening period (Day -30 to -1; V1); a treatment period ; and an off-treatment follow-up at Day 210 +/- 5 (V7). Unscheduled safety visits and early-discontinuation visits are performed as needed.
Endpoints: The primary endpoint is the albuminuria regression rate at 180 days, defined as a reduction in UACR KDIGO albuminuria category (A3 to A2 or A1, or A2 to A1) together with a >=30% reduction in UACR from baseline. Secondary endpoints include the change in UACR, the rate of regression to normoalbuminuria, the proportions achieving >=30/40/50% UACR reduction, KDIGO GFR-Albuminuria category improvement, the change in UACR 30 days after discontinuation, the change in eGFR slope, and the change in blood pressure. Safety endpoints include adverse events, serious adverse events, and adverse events of special interest (notably serum potassium changes and hyperkalemia). Exploratory endpoints also included.
Typ studie
Typ studie
Zápis (Odhadovaný)
Zápis
Fáze
Fáze
- Fáze 4
Kontakty a umístění
Studijní kontakt
Studijní kontakt
- Jméno: Yuejun Liu
- Telefonní číslo: +8613472844268
- E-mail: yuejunliu7@126.com
Studijní místa
-
-
Chongqing Municipality
-
Chongqing, Chongqing Municipality, Čína
- The First Affiliated Hospital of Chongqing Medical University
-
Kontakt:
- Zhihong Wang
- Telefonní číslo: +8613883021919
-
-
Fujian
-
Fuzhou, Fujian, Čína
- Fujian Provincial Hospital
-
Kontakt:
- Junping Wen
- Telefonní číslo: +8613559925729
-
-
Guangdong
-
Foshan, Guangdong, Čína
- Sanshui Hospital, Zhujiang Hospital, Southern Medical University
-
Kontakt:
- Zhen Zhang
- Telefonní číslo: +8615913162742
-
Guangzhou, Guangdong, Čína
- Nanfang Hospital, Southern Medical University
-
Kontakt:
- Junyu Xue
- Telefonní číslo: +8618613166333
-
-
Jiangsu
-
Nantong, Jiangsu, Čína
- Nantong First People's Hospital
-
Kontakt:
- Xueqin Wang
- Telefonní číslo: +8613813609566
-
Suqian, Jiangsu, Čína
- The First People's Hospital of Suqian
-
Kontakt:
- Hong Zhu
- Telefonní číslo: +8618012186759
-
Suzhou, Jiangsu, Čína
- Suzhou Science and Technology City Hospital
-
Kontakt:
- Zhimin Ma
- Telefonní číslo: +8617715187073
-
-
Shaanxi
-
Xi'an, Shaanxi, Čína
- Xi'an Daxing Hospital
-
Kontakt:
- Ying Xing
- Telefonní číslo: +8613991955717
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Čína
- Zhongshan hospital, Fudan university
-
Kontakt:
- Yuejuan Liu
- Telefonní číslo: +8613472844268
-
Shanghai, Shanghai Municipality, Čína
- Shanghai Municipal Hospital of Traditional Chinese Medicine
-
Kontakt:
- Feng Tao
- Telefonní číslo: +8613818808324
-
-
Zhejiang
-
Hangzhou, Zhejiang, Čína, 310003
- The First Affiliated Hospital, Zhejiang University School of Medicine
-
Kontakt:
- Peng Yu
- Telefonní číslo: 18818211531
- E-mail: ypbaggio@163.com
-
Ningbo, Zhejiang, Čína
- The First Affiliated Hospital of Ningbo University
-
Kontakt:
- Li Li
- Telefonní číslo: +8613757426626
-
Wenzhou, Zhejiang, Čína
- The First Affiliated Hospital of Wenzhou Medical University
-
Kontakt:
- Hong Zhu
- Telefonní číslo: +8613758712421
-
-
Kritéria účasti
Kritéria způsobilosti
Kritéria způsobilosti
Věk způsobilý ke studiu
- Dospělý
- Starší dospělý
Přijímá zdravé dobrovolníky
Popis
Inclusion Criteria:
- 1. Age >= 18 years at the time of signing informed consent, male or female.
- 2. Type 2 diabetes mellitus.
- 3. Chronic kidney disease meeting BOTH of the following: eGFR (CKD-EPI) >= 30 mL/min/1.73 m^2, and UACR 30-2000 mg/g (mean of 3 measurements).
- 4. Serum potassium <= 5.0 mmol/L.
- 5. On a maximum tolerated dose of an ACE inhibitor or ARB for at least 90 days.
- 6. Treatment with an SGLT-2 inhibitor, GLP-1 receptor agonist, or other agents affecting UACR is permitted, but the type and dose must be stable for at least 30 days before screening.
Exclusion Criteria:
- 1. Type 1 diabetes, other specific types of diabetes, or gestational diabetes.
- 2. HbA1c >= 8.0%.
- 3. On renal replacement therapy.
- 4. Acute kidney injury within 180 days before the screening visit.
- 5. Hepatic impairment (Child-Pugh class C).
- 6. Blood pressure > 160/100 mmHg, or systolic blood pressure < 90 mmHg, at the screening visit.
- 7. Bilateral renal artery stenosis.
- 8. Known hypersensitivity to the study drug (active substance or excipients).
- 9. Treatment with finerenone within 60 days before screening.
- 10. Stroke, transient ischemic attack, acute coronary syndrome (myocardial infarction, CABG, PCI), or hospitalization for worsening heart failure within 90 days before the screening visit.
- 11. NYHA class II-IV heart failure.
- 12. Addison's disease.
- 13. Gastrointestinal surgery that may affect drug absorption.
- 14. Any other history, condition, therapy, or uncontrolled concomitant disease that makes the participant unsuitable for the study or unlikely to complete it (e.g., active malignancy or other disease with life expectancy < 12 months).
- 15. Treatment with a strong CYP3A4 inhibitor (e.g., itraconazole, clarithromycin, ketoconazole, ritonavir, nelfinavir, cobicistat, telithromycin, nefazodone), a strong CYP3A4 inducer (e.g., carbamazepine, phenytoin, phenobarbital, St. John's wort), or a moderate CYP3A4 inducer (e.g., efavirenz) that cannot be discontinued for at least 7 days before randomization.
- 16. Treatment with another mineralocorticoid receptor antagonist (e.g., spironolactone, eplerenone, esaxerenone) or a potassium-sparing diuretic (e.g., amiloride, triamterene) that cannot be discontinued for at least 60 days before the screening visit.
- 17. Biopsy-confirmed non-diabetic kidney disease (e.g., IgA nephropathy).
- 18. Immunosuppressive therapy, or glucocorticoid use by any route other than topical or inhaled, within the past 180 days.
- 19. Participation in another interventional clinical study or use of any investigational product within 90 days before randomization.
- 20. History of alcohol or drug abuse.
- 21. Women of childbearing potential who are pregnant, breastfeeding, intend to become pregnant, or are not using adequate contraception during the study.
- 22. Any other condition deemed by the investigator to make the participant unsuitable for the study.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Trojnásobný
Počet zbraní
Zbraně a zásahy
Skupina účastníků / ArmSkupina účastníků / Arm |
Intervence / LéčbaIntervence / Léčba |
|---|---|
|
Experimentální: Finerenone
Finerenone film-coated tablets, orally once daily, on top of standard background therapy.
Starting dose determined by screening eGFR: 10 mg if 30 <= eGFR < 60 mL/min/1.73
m^2, or 20 mg if eGFR >= 60 mL/min/1.73
m^2.
Dose up-titrated to 20 mg, maintained, interrupted, or down-titrated to 10 mg based on serum potassium and eGFR.
Treatment duration 180 days.
|
Oral finerenone 10 mg or 20 mg once daily, with dose titration by serum potassium and eGFR, for 180 days.
|
|
Komparátor placeba: Placebo
Matching placebo tablets identical in appearance to finerenone, orally once daily, on top of standard background therapy, following the same dosing and titration schedule.
Treatment duration 180 days.
|
Matching placebo tablets, identical in appearance to finerenone, orally once daily, following the same dosing and titration schedule, for 180 days.
|
Co je měření studie?
Primární výstupní opatření
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Albuminuria regression rate
Časové okno: 180 days
|
Proportion of participants achieving albuminuria regression, defined as a reduction in UACR KDIGO albuminuria category (A3 to A2 or A1, or A2 to A1) together with a >=30% reduction in UACR from baseline.
|
180 days
|
Sekundární výstupní opatření
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Percent Change From Baseline in Urinary Albumin-to-Creatinine Ratio
Časové okno: Baseline and 180 days
|
Urinary albumin-to-creatinine ratio will be measured in mg/g.
Percent change from baseline will be calculated as: (Day 180 UACR - baseline UACR) / baseline UACR × 100%.
|
Baseline and 180 days
|
|
Percentage of Participants With Normoalbuminuria
Časové okno: 180 days
|
Normoalbuminuria is defined as urinary albumin-to-creatinine ratio less than 30 mg/g at Day 180.
|
180 days
|
|
Percentage of Participants by UACR Reduction Response Category at Day 180
Časové okno: Baseline to Day 180
|
Percent reduction in urinary albumin-to-creatinine ratio (UACR) from baseline to Day 180 will be calculated for each participant.
Participants will be classified into one of four mutually exclusive UACR reduction response categories: no more than 30% reduction, more than 30% to no more than 40% reduction, more than 40% to no more than 50% reduction, and more than 50% reduction.
Participants with no reduction or an increase in UACR will be included in the no more than 30% reduction category.
The outcome will be reported as the percentage of participants in each response category.
|
Baseline to Day 180
|
|
Percentage of Participants With Improvement in Kidney Disease: Improving Global Outcomes Albuminuria Category at Day 180
Časové okno: Baseline to Day 180
|
Improvement in albuminuria category is defined as a change from A3 to A2 or A1, or from A2 to A1, according to Kidney Disease: Improving Global Outcomes urinary albumin-to-creatinine ratio categories.
|
Baseline to Day 180
|
|
Change From Day 180 to Day 210 in Urinary Albumin-to-Creatinine Ratio
Časové okno: Day 180 to Day 210
|
Change in urinary albumin-to-creatinine ratio from Day 180 to Day 210 will be assessed in mg/g, corresponding to the 30-day off-treatment follow-up period.
|
Day 180 to Day 210
|
|
Estimated Glomerular Filtration Rate Slope Through Day 180
Časové okno: Baseline through Day 180
|
Estimated glomerular filtration rate will be calculated using the CKD-EPI equation.
The eGFR slope through Day 180 will be estimated from serial eGFR measurements and reported in mL/min/1.73
m2 per year.
|
Baseline through Day 180
|
|
Change From Baseline in Systolic Blood Pressure at Day 180
Časové okno: Baseline to Day 180
|
Change in systolic blood pressure from baseline to Day 180 will be assessed in mmHg.
|
Baseline to Day 180
|
|
Change From Baseline in Diastolic Blood Pressure at Day 180
Časové okno: Baseline to Day 180
|
Change in diastolic blood pressure from baseline to Day 180 will be assessed in mmHg.
|
Baseline to Day 180
|
Další výstupní opatření
Další výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Percentage of Participants With Adverse Events
Časové okno: From first dose through Day 210
|
The outcome will be reported as the percentage of participants experiencing at least one adverse event from first dose through the end of the 30-day off-treatment follow-up period.
|
From first dose through Day 210
|
|
Percentage of Participants With Serious Adverse Events
Časové okno: From first dose through Day 210
|
The outcome will be reported as the percentage of participants experiencing at least one serious adverse event from first dose through the end of the 30-day off-treatment follow-up period.
|
From first dose through Day 210
|
|
Adverse events of special interest (AESI)
Časové okno: Up to 210 days
|
Including change in serum potassium and incidence of hyperkalemia, incidence of eGFR decline >30% at Day 30, reversibility of eGFR after discontinuation, acute kidney injury, urogenital infection, severe hypoglycemia, symptomatic hypotension, and ketoacidosis
|
Up to 210 days
|
|
Change in Composite MRI-PDFF-derived Peri-organ Visceral Fat Fraction
Časové okno: Baseline and 180 days
|
Abdominal magnetic resonance imaging proton density fat fraction will be used to quantify visceral fat fraction (%) in prespecified perirenal, peripancreatic, and perihepatic regions of interest.
A composite peri-organ visceral fat fraction will be calculated for each participant as the arithmetic mean of the region-specific MRI-PDFF values from the perirenal, peripancreatic, and perihepatic regions.
The outcome will be reported as the percentage-point change in the composite peri-organ visceral fat fraction from baseline to Day 180.
|
Baseline and 180 days
|
|
Change in Urine Metabolomic Composite Score
Časové okno: Baseline to Day 180
|
Urine metabolomic features will be measured using a prespecified metabolomics platform.
Normalized metabolite feature intensities will be standardized, and a urine metabolomic composite score will be calculated according to the statistical analysis plan.
The outcome will be reported as change in composite score from baseline to Day 180.
|
Baseline to Day 180
|
Spolupracovníci a vyšetřovatelé
Sponzor
Sponzor
Publikace a užitečné odkazy
Obecné publikace
- Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, Joseph A, Kolkhof P, Nowack C, Schloemer P, Ruilope LM; FIGARO-DKD Investigators. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med. 2021 Dec 9;385(24):2252-2263. doi: 10.1056/NEJMoa2110956. Epub 2021 Aug 28.
- Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Nowack C, Schloemer P, Joseph A, Filippatos G; FIDELIO-DKD Investigators. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020 Dec 3;383(23):2219-2229. doi: 10.1056/NEJMoa2025845. Epub 2020 Oct 23.
- Heerspink HJ, Gao P, de Zeeuw D, Clase C, Dagenais GR, Sleight P, Lonn E, Teo KT, Yusuf S, Mann JF. The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial. Eur J Prev Cardiol. 2014 Mar;21(3):299-309. doi: 10.1177/2047487313510678. Epub 2013 Nov 4.
- Coresh J, Grams ME, Chen TK. Using GFR, Albuminuria, and Their Changes in Clinical Trials and Clinical Care. Am J Kidney Dis. 2021 Sep;78(3):333-334. doi: 10.1053/j.ajkd.2021.04.003. Epub 2021 May 28. No abstract available.
- Inker LA, Heerspink HJL, Tighiouart H, Chaudhari J, Miao S, Diva U, Mercer A, Appel GB, Donadio JV, Floege J, Li PKT, Maes BD, Locatelli F, Praga M, Schena FP, Levey AS, Greene T. Association of Treatment Effects on Early Change in Urine Protein and Treatment Effects on GFR Slope in IgA Nephropathy: An Individual Participant Meta-analysis. Am J Kidney Dis. 2021 Sep;78(3):340-349.e1. doi: 10.1053/j.ajkd.2021.03.007. Epub 2021 Mar 26.
- Lambers Heerspink HJ, Gansevoort RT. Albuminuria Is an Appropriate Therapeutic Target in Patients with CKD: The Pro View. Clin J Am Soc Nephrol. 2015 Jun 5;10(6):1079-88. doi: 10.2215/CJN.11511114. Epub 2015 Apr 17.
- Levey AS, Gansevoort RT, Coresh J, Inker LA, Heerspink HL, Grams ME, Greene T, Tighiouart H, Matsushita K, Ballew SH, Sang Y, Vonesh E, Ying J, Manley T, de Zeeuw D, Eckardt KU, Levin A, Perkovic V, Zhang L, Willis K. Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency. Am J Kidney Dis. 2020 Jan;75(1):84-104. doi: 10.1053/j.ajkd.2019.06.009. Epub 2019 Aug 28.
- Heerspink HJL, Greene T, Tighiouart H, Gansevoort RT, Coresh J, Simon AL, Chan TM, Hou FF, Lewis JB, Locatelli F, Praga M, Schena FP, Levey AS, Inker LA; Chronic Kidney Disease Epidemiology Collaboration. Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials. Lancet Diabetes Endocrinol. 2019 Feb;7(2):128-139. doi: 10.1016/S2213-8587(18)30314-0. Epub 2019 Jan 8.
- Fox CS, Matsushita K, Woodward M, Bilo HJ, Chalmers J, Heerspink HJ, Lee BJ, Perkins RM, Rossing P, Sairenchi T, Tonelli M, Vassalotti JA, Yamagishi K, Coresh J, de Jong PE, Wen CP, Nelson RG; Chronic Kidney Disease Prognosis Consortium. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet. 2012 Nov 10;380(9854):1662-73. doi: 10.1016/S0140-6736(12)61350-6. Epub 2012 Sep 24.
- Marup FH, Thomsen MB, Birn H. Additive effects of dapagliflozin and finerenone on albuminuria in non-diabetic CKD: an open-label randomized clinical trial. Clin Kidney J. 2023 Sep 26;17(1):sfad249. doi: 10.1093/ckj/sfad249. eCollection 2024 Jan.
- Agarwal R, Green JB, Heerspink HJL, Mann JFE, McGill JB, Mottl AK, Rosenstock J, Rossing P, Vaduganathan M, Brinker M, Edfors R, Li N, Scheerer MF, Scott C, Nangaku M; CONFIDENCE Investigators. Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes. N Engl J Med. 2025 Aug 7;393(6):533-543. doi: 10.1056/NEJMoa2410659. Epub 2025 Jun 5.
- Agarwal R, Tu W, Farjat AE, Farag YMK, Toto R, Kaul S, Lawatscheck R, Rohwedder K, Ruilope LM, Rossing P, Pitt B, Filippatos G, Anker SD, Bakris GL; FIDELIO-DKD and FIGARO-DKD Investigators. Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes : A Mediation Analysis. Ann Intern Med. 2023 Dec;176(12):1606-1616. doi: 10.7326/M23-1023. Epub 2023 Dec 5.
- Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Joseph A, Kolkhof P, Nowack C, Gebel M, Ruilope LM, Bakris GL; FIDELIO-DKD and FIGARO-DKD investigators. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022 Feb 10;43(6):474-484. doi: 10.1093/eurheartj/ehab777.
- 中华医学会糖尿病学分会, 国家基层公共卫生服务项目基础糖尿病防治管理办公室. 国家基层糖 尿病肾脏病防治技术指南 (2023). 中华内科杂志, 2023, 62(12): 1394-1405
- American Diabetes Association Professional Practice Committee. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2024. Diabetes Care. 2024 Jan 1;47(Suppl 1):S179-S218. doi: 10.2337/dc24-S010.
- Yang C, Wang H, Zhao X, Matsushita K, Coresh J, Zhang L, Zhao MH. CKD in China: Evolving Spectrum and Public Health Implications. Am J Kidney Dis. 2020 Aug;76(2):258-264. doi: 10.1053/j.ajkd.2019.05.032. Epub 2019 Sep 3.
- Wang L, Peng W, Zhao Z, Zhang M, Shi Z, Song Z, Zhang X, Li C, Huang Z, Sun X, Wang L, Zhou M, Wu J, Wang Y. Prevalence and Treatment of Diabetes in China, 2013-2018. JAMA. 2021 Dec 28;326(24):2498-2506. doi: 10.1001/jama.2021.22208.
- IDF ATLAS REPORTS: Diabetes and Kidney Disease- 2023. www.diabetesatlas.org
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Odhadovaný)
Začátek studia
Primární dokončení (Odhadovaný)
Primární dokončení
Dokončení studie (Odhadovaný)
Dokončení studie
Termíny zápisu do studia
První předloženo
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
První zveřejněno
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Poslední zveřejněná aktualizace
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
- Urogenitální onemocnění
- Onemocnění endokrinního systému
- Patologické procesy
- Mužská urogenitální onemocnění
- Onemocnění ledvin
- Urologická onemocnění
- Ženské urogenitální onemocnění
- Ženské urogenitální onemocnění a těhotenské komplikace
- Chronické onemocnění
- Atributy nemoci
- Metabolické choroby
- Poruchy močení
- Urologické projevy
- Poruchy metabolismu glukózy
- Diabetes Mellitus
- Renální insuficience
- Proteinurie
- Patologické stavy, příznaky a symptomy
- Nutriční a metabolické nemoci
- Příznaky a symptomy
- Diabetes mellitus, typ 2
- Renální insuficience, chronická
- Albuminurie
- Finerenone
Další identifikační čísla studie
Další identifikační čísla studie
- [2026C]IIT No.001
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .